Cysteinyl Leukotriene Receptor 2 (CYSLTR2) Antibody

Este producto es parte de CYSLTR - Cysteinyl Leukotriene Receptor
Product Graph
221€ (50 µg)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Cysteinyl Leukotriene Receptor 2 (CYSLTR2) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx324282
tested applications
ELISA, WB, IF/ICC

Description

CYSLTR2 Antibody is a Rabbit Polyclonal against CYSLTR2.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
Cysteinyl Leukotriene Receptor 2 (CYSLTR2)
Host
Rabbit
Reactivity
Human
Recommended Dilution
ELISA: 1/40000, WB: 1/500 - 1/2000, IF/ICC: 1/200 - 1/1000. Optimal dilutions/concentrations should be determined by the end user.
Clonality
Polyclonal
Conjugation
Unconjugated
Isotype
IgG
Purification
Purified by affinity chromatography.
Size 1
50 µg
Size 2
100 µg
Form
Liquid
Tested Applications
ELISA, WB, IF/ICC
Buffer
PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Availability
Shipped within 5-10 working days.
Storage
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Dry Ice
No
UniProt ID
Q9NS75
Gene ID
57105
Alias
CYSLTR2,CYSLT2,CYSLT2R,GPCR21,HG57,HPN321,KPG_011,PSEC0146,hGPCR21,LTC4
Background
Antibody anti-CYSLTR2
Status
RUO

Descripción

CYSLTR2 is a G protein-coupled receptor that binds cysteinyl leukotrienes, particularly LTC4 and LTD4, with a lower affinity for LTE4. CYSLTR2 is expressed in smooth muscle cells, endothelial cells, and immune cells, where it mediates inflammatory responses similar to CYSLTR1. CYSLTR2 activation leads to smooth muscle contraction, increased vascular permeability, and cytokine production through the phospholipase C (PLC)/calcium signaling pathway. While CYSLTR1 is more involved in acute bronchoconstriction, CYSLTR2 appears to play a complementary role in chronic inflammation, fibrosis, and tissue remodeling. Dysregulation of CYSLTR2 contributes to diseases such as asthma, pulmonary fibrosis, and cardiovascular conditions, where cysteinyl leukotriene signaling promotes tissue damage and chronic inflammation. Emerging evidence suggests CYSLTR2's involvement in cancer progression, particularly in promoting tumor-associated inflammation and angiogenesis. Targeting CYSLTR2, in combination with CYSLTR1 antagonists, is being explored to improve therapeutic outcomes in severe asthma, fibrosis, and inflammatory diseases.

Related Products

EH2923

Human CYSLTR2 (Cysteinyl Leukotriene Receptor 2) ELISA Kit

Ver Producto
ER0892

Rat CYSLTR2 (Cysteinyl Leukotriene Receptor 2) ELISA Kit

Ver Producto
QT-ER0892

Rat CYSLTR2 (Cysteinyl Leukotriene Receptor 2) QuickTest ELISA Kit

Ver Producto